Macchia B, Balsamo A, Breschi M C, Chiellini G, Lapucci A, Macchia M, Manera C, Martinelli A, Martini C, Scatizzi R
Istituto di Chimica Farmaceutica e Tossicologica, Università di Pisa, Italy.
J Med Chem. 1993 Oct 15;36(21):3077-86. doi: 10.1021/jm00073a006.
In previous papers dealing with the study of the conformations and the biopharmacological activity of conformationally restrained analogs of sympathomimetic catecholamines (NE and ISO), proposals were advanced for the three-dimensional molecular models A, B, and C; these models provided information about the steric requirements for the direct activation of alpha 1, alpha 2,beta 1, and beta 2 adrenoceptors, respectively. The 1-(aminomethyl)-6,7-dihydroxyisochromans 11 and 12 and the 1-(aminomethyl)-5,6-dihydroxyisochromans 13 and 14 (1-AMDICs) are two different types of semirigid analogs of NE and ISO. The alpha 1, alpha 2, beta 1, and beta 2 adrenergic properties of the 1-AMDICs 11-14 were evaluated in vitro, both by radioligand binding assays and by functional tests on isolated preparations, and were compared with those of their parent compounds (NE and ISO). The results of a conformational study carried out by means of both 1H NMR spectrometry and theoretical calculations indicated that, in these 1-AMDICs, the presumed active groups (aryl moiety, amine nitrogen and benzylic ethereal oxygen) are in a spatial relationship corresponding to the one found for NE and ISO in their preferred conformations, which also proved to be the pharmacophoric conformation in the models A-C. By means of a comparison of the stereostructures of the 1-AMDICs 11-14 with their biopharmacological properties, it was possible to obtain a further definition of the model B with respect to the activation of the alpha 2 adrenoceptors; the superimposition of the 1-AMDICs 11 and 12 with the molecular model C made it possible to detect an area of the beta-adrenergic receptors which might hinder the fit of adrenergic drugs that are analogs of catecholamines with these receptors.
在之前关于拟交感神经儿茶酚胺(去甲肾上腺素和异丙肾上腺素)构象受限类似物的构象及生物药理学活性研究的论文中,曾提出三维分子模型A、B和C;这些模型分别提供了关于直接激活α1、α2、β1和β2肾上腺素能受体的空间要求的信息。1-(氨甲基)-6,7-二羟基异苯并二氢吡喃11和12以及1-(氨甲基)-5,6-二羟基异苯并二氢吡喃13和14(1-AMDICs)是去甲肾上腺素和异丙肾上腺素的两种不同类型的半刚性类似物。通过放射性配体结合试验和对分离制剂的功能测试,在体外评估了11-14号1-AMDICs的α1、α2、β1和β2肾上腺素能特性,并将其与它们的母体化合物(去甲肾上腺素和异丙肾上腺素)的特性进行了比较。通过1H NMR光谱法和理论计算进行的构象研究结果表明,在这些1-AMDICs中,假定的活性基团(芳基部分、胺氮和苄基醚氧)处于一种空间关系中,这种关系与去甲肾上腺素和异丙肾上腺素在其优选构象中所发现的关系相对应,而这种构象在模型A-C中也被证明是药效构象。通过比较11-14号1-AMDICs的立体结构与其生物药理学特性,有可能进一步明确模型B关于α2肾上腺素能受体激活的情况;11和12号1-AMDICs与分子模型C的叠加使得有可能检测到β-肾上腺素能受体的一个区域,该区域可能会阻碍儿茶酚胺类似物的肾上腺素能药物与这些受体的契合。